Positioning of proteasome inhibitors in therapy of solid malignancies
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagic cell death: the story of a misnomer
Kroemer, G., & Levine, B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2529 · Cited by 1,453 · cited 2×
“Low or moderate levels of autophagy appear cell-protective, while high levels of autophagy facilitate promotion of cell death [102, 103].”
BackgroundHDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024 · cited 1×
“Given the high protein turnover and the critical role of the UPS in the development, cell growth and survival of cancer cells [19, 25], proteasome inhibition constitutes an attractive target for chemotherapeutic intervention [4, 26, 27].”
BackgroundOrchestrating the unfolded protein response in health and disease
Kaufman, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216886 · Cited by 1,015 · cited 1×
“There are three ER stress sensors that initiate UPR: PKR-like ER kinase (PERK), inositol requiring kinase 1 (IRE1α), and activating transcription factor (ATF6) [32, 33].”
BackgroundDing, W.-X., Ni, H.-M., Gao, W., Yoshimori, T., Stolz, D. B., Ron, D., & Yin, X.-M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070188 · Cited by 708
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122 · cited 3×
“Marked BTZ- induced apoptosis and antitumor activity was noted in TNBC in vitro and in vivo, but not in HER2-overexpressing and estrogen receptor-positive breast cancer cell lines [108].”
BackgroundPositioning of aminopeptidase inhibitors in next generation cancer therapy
Hitzerd, S. M., Verbrugge, S. E., Ossenkoppele, G., Jansen, G., & Peters, G. J. (2014) · Amino Acids · doi:10.1007/s00726-013-1648-0 · Cited by 95 · cited 1×
“, glucose and amino acid metabolism) in PI-resistant cells, interfering with these pathways might constitute novel strategies to enhance PI’s cytotoxicity in combination therapies [22].”
BackgroundSelf-citationNew orally active proteasome inhibitors in multiple myeloma
Allegra, A., Alonci, A., Gerace, D., Russo, S., Innao, V., Calabrò, L., & Musolino, C. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.10.018 · Cited by 74
Cited by
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Copy number variation is highly correlated with differential gene expression: a pan-cancer study
Shao, X., Lv, N., Liao, J., Long, J., Xue, R., Ai, N., Xu, D., & Fan, X. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0909-5 · Cited by 320
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50
P53: Stability from the Ubiquitin–Proteasome System and Specific 26S Proteasome Inhibitors
do Patrocinio, A. B., Rodrigues, V., & Guidi Magalhães, L. (2022) · ACS Omega · doi:10.1021/acsomega.1c04726 · Cited by 36
Metadata
- Authors
- Roeten, M. S. F., Cloos, J., & Jansen, G.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2017-11-28
- Volume
- 81
- Issue
- 2
- Pages
- 227-243
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2768999031
- Cited by
- 145
- References
- 8
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.